Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Opioid Use Disorder (OUD)

Psilocybin for Opioid Use Disorder (OUD)

11 papers and 9 clinical trials exploring psilocybin as a treatment for opioid use disorder (oud).

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationAn estimated 2 million people in the United States have OUD.

Opioid Use Disorder (OUD)

Opioid Use Disorder (OUD) is a prevalent and serious public health issue that is increasingly being targeted for treatment with psychedelics, particularly ibogaine. Recent studies suggest that these compounds may alleviate withdrawal symptoms and reduce cravings, presenting a potential shift in therapeutic approaches to OUD.

Full Opioid Use Disorder (OUD) profile

Academic Research

11 papers
Paywallindividual

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings

This safety-feasibility trial (n=2) explored the interaction between psilocybin and buprenorphine in adults with opioid use disorder (OUD). The study found that coadministration of psilocybin and buprenorphine was safely tolerated, with no serious adverse events or significant changes in opioid craving or withdrawal measures. Feasibility challenges led to modifications in the study population and eligibility criteria, emphasizing the need for improved accessibility and overall generalizability.

Published
December 4, 2023
Journal
Psychedelic Medicine
Authors
Nicholas, C. R., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., Brown, R. T.
Open Accessindividual

Associations between classic psychedelics and nicotine dependence in a nationally representative sample

In a nationally representative sample of 214,505 US adults, lifetime use of psilocybin, peyote and mescaline was associated with modestly lower odds of current nicotine dependence, whereas lifetime LSD use was associated with higher odds; experimental studies are needed to establish causality and assess therapeutic potential for smoking cessation.

Published
June 22, 2022
Journal
Scientific Reports
Authors
Jones, G. M., Lipson, J., Nock, M. K.
Open Accessindividual

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Using data from the National Survey on Drug Use and Health (2015–2019; N = 214,505), lifetime psilocybin use was associated with significantly lower odds of opioid use disorder (adjusted OR 0.70, 95% CI 0.60–0.83), while other classic psychedelics showed no such association, and psilocybin use was linked to reduced odds for seven of 11 DSM‑IV OUD criteria. These observational findings suggest psilocybin merits further investigation in longitudinal and clinical trials to assess causality.

Published
April 7, 2022
Journal
Scientific Reports
Authors
Jones, G. M., Ricard, J. A., Lipson, J., Nock, M. K.
Paywallmeta

Beating Pain with Psychedelics: Matter over Mind?

This review (2021) makes the case for using psychedelics to treat pain. Key areas discussed include studies that have directly used psychedelics to treat pain, potential neuro-restorative effects of psychedelics in pain-related states of consciousness, anti-neuroinflammatory and pro-immunomodulatory actions of psychedelics and the safety, legal, and ethical consideration inherent in psychedelics’ pharmacotherapy. Psychedelics could also help to elucidate the mechanism of pain syndromes.

Published
March 1, 2022
Journal
Neuroscience and Biobehavioral Reviews
Authors
Elman, I., Borsook, D., Pustilink, A.
Open Accessindividual

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Pooled 2015–2018 NSDUH data from 168,650 US adults show 9.68% reported lifetime psilocybin use, with higher prevalence among bisexual-identifying individuals and substantial overlap with LSD, methamphetamine and heroin users. These findings can inform harm-reduction efforts and behavioural‑health messaging.

Published
May 11, 2021
Journal
Journal of Psychedelic Studies
Authors
Yockey, R. A., King, K. A.
Paywallmeta

Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature

This paper (2021) reviews the current literature regarding LSD, psilocybin, ketamine, ibogaine, and ayahuasca as potential treatments for addiction. The authors conclude that the available evidence is promising, but that more robust research is needed.

Published
March 31, 2021
Journal
SN Comprehensive Clinical Medicine
Authors
Nigam, K. B., Pandurangi, A. K.

Clinical Trials

9 trials
RecruitingPhase II

Psilocybin for Opioid Use Disorder (OUD)

Double-blind, adaptive, two-stage, multi-site, Phase II randomised trial (up to 480 consented to yield 240 randomized) comparing single moderate (20 mg) and high (30 mg) doses of oral psilocybin with low-dose (1 mg) control in OUD patients on methadone.

Started
March 1, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06796062
RecruitingPhase II

Psilocybin on Brain Mechanisms of Motivation in OUD

Randomised, quadruple-masked Phase II trial (n=24) comparing single low (1 mg) vs high (25 mg) PEX010 psilocybin doses to study motivation/reward and cognitive flexibility circuits in people with opioid use disorder.

Started
March 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06810310
RecruitingPhase II

Wellcome Leap Psilocybin for OUD

Triple-blind, randomised, parallel-group Phase II trial (n=36) testing a single 25 mg vs 1 mg PEX010 psilocybin dose (2:1) in individuals on MAT for opioid use disorder to assess neural and clinical outcomes including urine drug screens and MAT adherence.

Started
February 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06786325
RecruitingPhase II

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

This double-blind, controlled trial (n=90) aims to investigate the effect of a single high dose of psilocybin therapy (30mg) versus a very low dose (1mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid Use Disorder (OUD).

Started
February 8, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06067737
RecruitingPhase I

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Single-group study (n=12) of a single oral psilocybin dose (20–25 mg, weight-based) assessing synaptotrophic effects with pre/post [11C]-UCB-J PET and fMRI in detoxified individuals with opioid use disorder (OUD).

Started
January 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06160284
WithdrawnPhase II

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-In)

Double-blind, controlled trial (n=90) comparing a single high-dose psilocybin session (30 mg) versus a very low dose (1 mg) as adjunctive therapy to standard buprenorphine treatment for OUD.

Started
December 1, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06005662

Explore further

Search all Psilocybin papers Search all Opioid Use Disorder (OUD) trials Full Psilocybin profile Full Opioid Use Disorder (OUD) profile